Table 3.
Perinatal mortality (stillbirths plus neonatal deaths) by exposure group
| Artemether-lumefantrine (N = 475) |
Sulphadoxine-pyrimethamine (N = 480) |
||||
|---|---|---|---|---|---|
| Perinatal mortality (primary outcome) - n (%) | 20 (4.2) | 24 (5.0) | |||
| Asymptotic 95% CI | 2.4 - 6.0 | 3.1 - 6.9 | |||
| Pearson-Clopper 95% CI | 2.6 - 6.4 | 3.2 - 7.3 | |||
| Stillbirth - n (%) | 9 (1.9) | 13 (2.7) | |||
| Neonatal death ≤7 days after birth - n (%) | 11 (2.3) | 11 (2.3) | |||
| Exposure to anti-malarial agent(s) during first trimester* | |||||
| AL only (N = 135) | AL + SP (N = 7) | SP or/and quinine (N = 129) | None (N = 644) | Unknown (N = 40) | |
| Perinatal mortality - n (%) | 6 (4.4) | 1 (14.3) | 5 (3.9) | 31 (4.8) | 1 (2.5) |
| Stillbirth (>28 weeks gestation) | 2 (1.5) | 0 (0) | 3 (2.3) | 17 (2.6) | 0 (0) |
| Death ≤7 days after birth | 4 (3.0) | 1 (14.3) | 2 (1.6) | 14 (2.2) | 1 (2.5) |
Enrolled population: newborns and stillbirths.
Perinatal mortality: stillbirth or early neonatal death within 7 days after birth.
AL = artemether-lumefantrine; CI = confidence interval; SP = sulphadoxine-pyrimethamine.
* Data from newborns and stillbirths with known delivery status.